drugset / Trial / NCT00782041
Patients Who Have Failed First Line Treatment for Locally Advanced and/or Metastatic Cervical Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary: * To assess the overall response rate of oxaliplatin in patients with bidimensionally measurable disease at baseline. Secondary: * To assess the safety and tolerability of oxaliplatin * To assess time to progression and overall survival.
Timeline
- Start
- 2003-01
- Primary completion
- 2003-08
- Completion
- —
Outcome
Outcome not reported
Stopped: “protocol violation”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | Leucovorin | Small molecule | 20 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2000 mg/m2 | — |